Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
| Autor: | Orkin, Chloe, DeJesus, Edwin, Sax, Paul E, Arribas, Jose R, Gupta, Samir K, Martorell, Claudia, Stephens, Jeffrey L, Stellbrink, Hans-Jurgen, Wohl, David, Maggiolo, Franco, Thompson, Melanie A, Podzamczer, Daniel, Hagins, Debbie, Flamm, Jason A, Brinson, Cynthia, Clarke, Amanda, Huang, Hailin, Acosta, Rima, Brainard, Diana M, Collins, Sean E *, Martin, Hal |
|---|---|
| Zdroj: | In The Lancet HIV June 2020 7(6):e389-e400 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|